<DOC>
	<DOC>NCT01234298</DOC>
	<brief_summary>To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms of schizophrenia.</brief_summary>
	<brief_title>SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Subject has diagnosis of schizophrenia for at least 2 years Subject has persistent predominant negative symptoms Subject has 2 or more persistent predominant negative symptoms (affective flattening, alogia, avolition apathy, and anhedoniaasociality) determined to have been present for at least 6 months Subject is maintained on antipsychotic monotherapy or polytherapy with no more than 2 antipsychotic medications Subject has been clinically stable and is in the nonacute phase of illness Subject has clinically notable positive symptoms Subject is considered to be treatment refractory Subject has current history of substance abuse/dependance Subject is considered a suicide risk or risk to harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>